ZaBeCor Overview
ZaBeCor is a clinical stage biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of asthma, allergy and other inflammatory and infectious diseases.
ZaBeCor’s intellectual property portfolio, which is exclusively licensed from the University of Pennsylvania, includes U.S. and international patents related to the following drug candidates:
| Drug Candidate Name | Type of Technology | Potential Use/Indication |
| Excellair™ | Anti-Inflammatory | Treatment of asthma, allergy, ARDS, COPD, avian flu inflammation, uveitis, cystitis, rheumatoid arthritis and other autoimmune and inflammatory diseases |
| Recruitin™ | Phagocytosis-inducing | Immune system modulator for infection based on gene therapy |
| Disarmin™ | Phagocytosis-inhibiting | Immune system modulator for autoimmune diseases based on gene therapy |
| Hematrol™ | Steroid analog without the toxicity of glucocorticoids (prednisone) | Low blood platelets (ITP), anemia (hemolytic), rheumatoid arthritis, systemic lupus, ulcerative colitis, Crohn’s Disease, psoriasis, and other steroid responsive autoimmune disorders. |